GSK2982772 clinical trials
Also written GSK2982772.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses GSK2982772 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses GSK2982772 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis ParticipantsCompletedPhase 1GlaxoSmithKlineNCT04316585Written as GSK2982772
- A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT03305419Written as GSK2982772 capsule
- Phase I Study of GSK2982772 in Japanese Healthy Male ParticipantsCompletedPhase 1GlaxoSmithKlineNCT03590613Written as GSK2982772
- A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat DosesCompletedPhase 1GlaxoSmithKlineNCT03266172Written as GSK2982772 Modified Release
- Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)CompletedPhase 2GlaxoSmithKlineNCT02858492Written as GSK2982772 60 mg
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With PsoriasisCompletedPhase 2GlaxoSmithKlineNCT02776033Written as GSK2982772
- GSK2982772 Study in Subjects With Ulcerative ColitisCompletedPhase 2GlaxoSmithKlineNCT02903966Written as GSK2982772
- A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772CompletedPhase 1GlaxoSmithKlineNCT03649412Written as GSK2982772 Modified Release
- A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male SubjectsCompletedPhase 1GlaxoSmithKlineNCT02302404Written as GSK2982772 solution